Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 10/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9844004 | 0.99 | CYP19A1 (0.61) | CYP19A1TBXAS1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL9843746 | 0.84 | CYP19A1 (0.57) | CYP19A1TBXAS1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL9843743 | 0.83 | CYP19A1 (0.56) | CYP19A1TBXAS1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL7573772 | 0.81 | TBXAS1 (0.46) | CYP19A1TBXAS1CYP11B1CYP11B2ATM | |
| SCHEMBL8869750 | 0.80 | CYP19A1 (0.69) | CYP19A1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL2352579 | 0.79 | CYP19A1 (0.52) | CYP19A1TBXAS1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL2355216 | 0.77 | CYP19A1 (1.00) | CYP19A1CYP11B1CYP11B2CYP17A1 | |
| Hydrochloric Acid SCHEMBL9844041 | 0.76 | CYP19A1 (0.98) | CYP19A1CYP11B1CYP11B2CYP17A1 | |
| Hydrochloric Acid SCHEMBL9843801 | 0.73 | CYP19A1 (0.59) | CYP19A1TBXAS1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL2352950 | 0.70 | PARP1 (0.38) | CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0445073-A1 | Benzofurans | CIBA-GEIGY AG (CH) | 1991-09-04 | — | — | EP | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| CN-100593401-C | Combination of an aromatase inhibitor with a bisphosphonate | NOVARTIS AG | 2010-03-10 | — | — | CN | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1898923-A1 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | Casper, Robert F. (CA) | 2008-03-19 | — | — | EP | disclosed |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | ARES TRADINS S.A. (CH) | 2004-09-02 | — | — | US | disclosed |
| WO-2002083240-A9 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING SA (CH) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004012728-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | disclosed |
| EP-1383578-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2004-01-28 | — | — | EP | disclosed |
| EP-1381431-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003082336-A1 | FEMALE BIRTH CONTROL METHOD | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002083241-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083239-A1 | AROMATASE INHIBITORS FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083240-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP19A1 1/4885TBXAS1 127/4885CYP11B1 20/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | CYP19A1 7/4885TBXAS1 1301/4885CYP11B1 525/4885 |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | CYP19A1, FSHR, SHBG | CYP19A1 1/4885TBXAS1 1642/4885CYP11B1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.